MPS 2 – Patient Worthy

FDA Places Clinical Hold on REGENXBIO’s MPS Gene Therapy Programs After Tumor Case Review

Post author:Austin Newman
Post published:February 4, 2026
Post category:Hunter Syndrome

As reported on Drugs.com, REGENXBIO has announced that the U.S. Food and Drug Administration (FDA) has halted clinical testing of its investigational gene therapies RGX‑111 and RGX‑121, two programs targeting…

UNC Researchers Report Promising Advances Toward First Brain‑Targeting Enzyme Therapy for Hunter Syndrome

Post author:Austin Newman
Post published:January 15, 2026
Post category:Hunter Syndrome

As reported by NewsWise, new clinical study led by investigators at the University of North Carolina at Chapel Hill is offering rare hope for families affected by Hunter syndrome, a…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More